NEW Report Just Added!
This report covers several technologies, epigenetic targets, and market outlook. The first part of this report covers necessary background information, mostly pertaining to epigenetic targets, and the reasons they are being investigated. Several companies have kindly disclosed several strategies, methods, and techniques that they use for either target identification or technology development.
Report Features Include:
- Survey data results
- Company background information
- Interviews with CEOs, CSOs, and Expert Scientists
- Specific pharmaceutical/biopharmaceutical companies and their strategies
In Part I of the report, several targets and their properties are discussed including histone methyltransferases, histone demethylases, and bromodomains. A list of known histone modifications is also present. This includes companies (if applicable), targets being studied, diseases they are associated with, and their clinical developmental status. Part II details specific pharmaceutical/biopharmaceutical companies and their strategies behind their target identifications and validation. These companies include Constellation Pharmaceuticals, Epizyme Inc., and EpiTherapeutics. Part III of the report covers technologies and assays available from the following biotechnology companies: Active Motif (including ChIP technology and a current list of validated antibodies), Cayman Chemical, and Reaction Biology.
Areas covered for Parts I and II include:
- Company backgrounds
- Areas of interest
- Challenges encountered
- Competitive advantages
Additionally, these sections also include interviews with CEOs, CSOs, and expert scientists of the participating companies.
The last section of the report, Part IV, gives insight into the epigenetics community. Insight Pharma Reports polled a survey which had more than 150 responses. Specific areas highlighted are targets under investigation, market outlook, and how partnerships with external organizations have advanced the industry.